Pfizer pays $155 million for TransTech's Alzheimer's compounds

By Elaine Rigoli

Tampa, Fla., Sept. 18 - Pfizer, Inc. and TransTech Pharma, Inc. have entered into a license agreement for the development and commercialization of advanced glycation end products (RAGE) for potential use in the treatment of Alzheimer's disease.

Under the agreement, TransTech will receive upfront and near-term milestone payments of $155 million and the potential for additional milestone payments for the successful development and commercialization of multiple RAGE antagonists in several indications.

TransTech, a clinical-stage pharmaceutical company based in High Point, N.C., will receive royalties on worldwide sales of products.

Pfizer, a New York pharmaceutical company, said it will provide TransTech additional funding during the research term to support continued expansion of the RAGE portfolio.

Through the collaboration, Pfizer gains exclusive worldwide rights to develop and commercialize TransTech's portfolio of RAGE modulators. The company said the most advanced molecules are TTP488, an orally available small-molecule compound that has completed a phase 2a study in Alzheimer's patients and is in a phase 2 study in patients with diabetic nephropathy; and TTP4000, a large-molecule compound that is expected to enter phase 1 clinical trials before the end of 2006.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.